Detalhe da pesquisa
1.
Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis.
N Engl J Med
; 385(1): 46-58, 2021 07 01.
Artigo
Inglês
| MEDLINE | ID: mdl-34192431
2.
The lymphocyte/monocyte ratio predicts the efficacy of isatuximab plus pomalidomide in multiple myeloma patients.
Cancer Immunol Immunother
; 73(7): 135, 2024 May 17.
Artigo
Inglês
| MEDLINE | ID: mdl-38758239
3.
Efficacy of elotuzumab for multiple myeloma deteriorates after daratumumab: a multicenter retrospective study.
Ann Hematol
; 2024 Mar 16.
Artigo
Inglês
| MEDLINE | ID: mdl-38492020
4.
Anti-CD38 antibody isatuximab monotherapy for Japanese individuals with relapsed/refractory multiple myeloma: An update of the phase 1/2 ISLANDs study.
Hematol Oncol
; 41(3): 442-452, 2023 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-36433829
5.
Daratumumab plus bortezomib, cyclophosphamide, and dexamethasone in Asian patients with newly diagnosed AL amyloidosis: subgroup analysis of ANDROMEDA.
Ann Hematol
; 102(4): 863-876, 2023 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-36862168
6.
Plateau is a prognostic factor of lenalidomide therapy for previously treated multiple myeloma.
Hematol Oncol
; 39(3): 349-357, 2021 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-33724498
7.
Outcomes of ixazomib/lenalidomide/dexamethasone for multiple myeloma: A multicenter retrospective analysis.
Eur J Haematol
; 106(4): 555-562, 2021 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-33476404
8.
Isatuximab monotherapy in relapsed/refractory multiple myeloma: A Japanese, multicenter, phase 1/2, safety and efficacy study.
Cancer Sci
; 111(12): 4526-4539, 2020 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-32975869
9.
Factors Associated with Dose Modification of Lenalidomide Plus Dexamethasone Therapy in Multiple Myeloma.
Biol Pharm Bull
; 43(8): 1253-1258, 2020.
Artigo
Inglês
| MEDLINE | ID: mdl-32741946
10.
[Current diagnosis and treatment of AL amyloidosis in Japan: a nationwide epidemiological survey].
Rinsho Ketsueki
; 60(8): 973-978, 2019.
Artigo
Japonês
| MEDLINE | ID: mdl-31484898
11.
[Spontaneous regression of primary gastric EBV-positive diffuse large B-cell lymphoma].
Rinsho Ketsueki
; 60(11): 1573-1576, 2019.
Artigo
Japonês
| MEDLINE | ID: mdl-31839637
12.
[Successful treatment of relapse/refractory multiple myeloma with carfilzomib, lenalidomide, and dexamethasone combination therapy following allogeneic bone marrow transplantation].
Rinsho Ketsueki
; 60(10): 1468-1470, 2019.
Artigo
Japonês
| MEDLINE | ID: mdl-31695009
13.
[Latent essential thrombocythemia becoming perceptible after splenectomy].
Rinsho Ketsueki
; 60(5): 387-391, 2019.
Artigo
Japonês
| MEDLINE | ID: mdl-31168000
14.
The serum level of plasmin-alpha2 plasmin inhibitor complex (PIC) is useful for differentiating cardiac light chain amyloidosis from transthyretin amyloidosis.
Br J Haematol
; 202(6): 1209-1212, 2023 09.
Artigo
Inglês
| MEDLINE | ID: mdl-37424146
15.
Unsuppressed serum albumin levels may jeopardize the clinical relevance of the international staging system to patients with light chain myeloma.
Hematol Oncol
; 36(5): 792-800, 2018 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-30176173
16.
[Agranulocytosis during therapy of chronic myeloid leukemia lymphoid blast crisis with dasatinib].
Rinsho Ketsueki
; 59(11): 2438-2440, 2018.
Artigo
Japonês
| MEDLINE | ID: mdl-30531140
17.
[Possible contribution of disseminated Mycobacterium shigaense infection to development of splenic marginal zone lymphoma].
Rinsho Ketsueki
; 59(7): 878-883, 2018.
Artigo
Japonês
| MEDLINE | ID: mdl-30078797
18.
CEA-producing multiple myeloma with meningeal invasion during relapse.
Rinsho Ketsueki
; 58(5): 438-442, 2017.
Artigo
Japonês
| MEDLINE | ID: mdl-28592756
19.
Renal artery stenosis following nilotinib administration in a patient with chronic myelogenous leukemia.
Rinsho Ketsueki
; 58(1): 15-19, 2017.
Artigo
Japonês
| MEDLINE | ID: mdl-28190859
20.
Quincke's edema and hypersensitivity pneumonitis induced by lenalidomide for multiple myeloma.
Rinsho Ketsueki
; 57(12): 2502-2506, 2016.
Artigo
Japonês
| MEDLINE | ID: mdl-28090017